Provision of Psychopharmacological Services in Nursing Homes

Abstract

We examined the psychopharmacological services provided within 3 months of nursing home (NH) admission to a whole population of newly admitted Florida NH residents 65 years and older (N = 947) for a 1-year period via secondary analyses of selected variables from Medicaid and the Online Survey and Certification and Reporting System. Within 3 months of admission, 12% received nonpsychopharmacological mental health care. However, 71% of new residents received at least one psychoactive medication, and more than 15% were taking four or more psychoactive medications. Most of those being treated with psychoactive medication had not received psychopharmacological treatment 6 months prior to admission (64%) and had not received a psychiatric diagnosis 6 months preceding admission (71%). Blacks were less likely to receive medications than non-Hispanic Whites. Results expand on past research by identifying an increase in the amount of psychoactive medications prescribed to NH residents, a lack of prior psychiatric treatment and diagnoses for those currently receiving psychoactive medications, only limited provision of nonpsychopharmacological mental health care, and racial or ethnic differences in the use of medications by NHs.

Management of Neuropsychiatric Symptoms of Dementia in Clinical Settings: Recommendations from a Multidisciplinary Expert Panel

“…In the latter cases, the standard of care supports psychotropic use in the absence of data. Unfortunately, effective non-pharmacologic strategies for NPS have not been translated into real-world clinical management and standard care [20]. Despite major concerns about safety and efficacy, psychotropics remain the primary “go-to” treatment approach, often without systematic assessment of potential underlying causes [21].…”

Association of the Centers for Medicare & Medicaid Services’ National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014

“…[1][2][3] Nonpharmacologic interventions-better stated as behavioral and environmental interventions-are recommended by numerous guidelines, medical organizations, and expert groups as the preferred first-line treatment, [4][5][6][7] although they have largely not been translated into routine clinical practice. 8 Despite the fact that no drugs have been approved by the US Food and Drug Administration (FDA) for the behavioral and psychological symptoms of dementia, the current mainstay of treatment is the off-label use of psychotropic medications. 9,10 Of such agents, atypical antipsychotics have the strongest base of evidence, although their benefits are moderate at best and they are associated with a significant increase in the risk of stroke and mortality.…”

Unintentional self-injury of the tongue in an aged patient with Alzheimer's disease and behavioral and psychological symptoms of dementia, successfully treated with Kampo medicine: A case report

“…For these patients, psychological interventions for BPSD are the first-line treatment and take precedence over pharmacological treatment [5]. But there is no standard psychological intervention for BPSD [9]. In the community-dwelling, aged population with dementia, psychological interventions having the strongest evidence base involve family caregivers who are well trained, as well as staff members in long-term care facilities [5].…”